## **SUPPORTING INFORMATION**

## Preventing Staphylococci Surgical Site Infections with a Nitric Oxide-Releasing

## Poly(lactic acid-co-glycolic acid) Suture Material

Lauren Griffin<sup>a</sup>, Mark Richard Stephen Garren<sup>a</sup>, Patrick Maffe<sup>a</sup>, Sama Ghalei<sup>a</sup>, Elizabeth J. Brisbois<sup>a</sup>, and Hitesh Handa<sup>ab</sup>\*

<sup>a</sup> School of Chemical, Materials and Biomedical Engineering, College of Engineering, University of Georgia, Athens, GA, 30602, USA

<sup>b</sup> Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, 30602, USA

\* Corresponding Author:

Dr. Hitesh Handa Associate Professor University of Georgia 302 East Campus Road Athens, GA, 30602, USA Telephone: (706) 542-8109 E-mail: <u>hhanda@uga.edu</u>



**Figure S1.** Representative UV-vis spectra of SNAP in THF, demonstrating the S-nitrosothiol bond peak on the SNAP molecule at 340 nm (molar absorptivity =  $0.40 \text{ mL mg}^{-1} \text{ mm}^{-1}$ ).

**Table S1.** SNAP loading and leaching for various swelling solution concentrations. Data is represented as mean  $\pm$  SD (n = 3).

Swelling Solution (mg mL <sup>-1</sup> )	SNAP Loading ( <i>wt</i> %)	12 h SNAP Leaching ( <i>wt</i> %)	
25	0.73 ± 0.17	$0.52 \pm 0.05$	
50	1.88 ± 0.08	1.17 ± 0.13	
75	1.84 ± 0.07	n/a	
100	2.09 ± 0.17	n/a	



**Figure S2.** Representative images from zone of inhibition assay for (A) *S. aureus* and (B) MRSA. On each agar plate, unmodified PLGA is on the left, and NOrel-PLGA is on the right.

**Table S2.** Planktonic reduction against *S. aureus* and MRSA. Data is represented as mean  $\pm$  SD (n = 3).

Sample	Unit	S. aureus	MRSA
<b>Inoculum</b> (Control)	CFU mL <sup>-1</sup>	1.88 ± 0.16 (x10 <sup>7</sup> )	5.02 ± 0.54 (x10 <sup>7</sup> )
	Log reduction wrt. Control	n/a	n/a
	p value wrt. Control	n/a	n/a
Unmod. PLGA	CFU mL <sup>-1</sup>	1.07 ± 0.23 (x10 <sup>7</sup> )	3.28 ± 1.20 (x10 <sup>7</sup> )
	Log reduction wrt. Control	0.25	0.18
	p value wrt. Control	0.3450	0.7766
NOrel- PLGA	CFU mL <sup>-1</sup>	2.95 ± 1.60 (x10 <sup>5</sup> )	4.50 ± 4.06 (x10 <sup>4</sup> )
	Log reduction wrt. Control	1.80	3.05
	p value wrt. Control	< 0.0001	< 0.0001

**Table S3.** Adhered reduction against *S. aureus* and MRSA. Data is represented as mean  $\pm$  SD (n = 3).

Sample	Unit	S. aureus	MRSA
Unmod. PLGA	CFU mL <sup>-1</sup>	1.15 ± 0.17 (x10 <sup>5</sup> )	4.93 ± 2.04 (x10 <sup>4</sup> )
	Log reduction wrt. Control	n/a	n/a
	p value wrt. Control	n/a	n/a
NOrel- PLGA	CFU mL <sup>-1</sup>	1.06 ± 0.05 (x10 <sup>4</sup> )	2.75 ± 1.18 (x10 <sup>2</sup> )
	Log reduction wrt. Control	1.03	2.25
	p value wrt. Control	< 0.0001	< 0.0001



**Figure S3.** MIC results for SNAP against *S. aureus* and MRSA. Data is represented as mean  $\pm$  SD (n = 3).